Latest Publications

See all publications >

NHS 32nd Annual Conference

20th & 21st November, Nottingham

£550.00

Please note:
We do not currently accept AMEX payments via the website. Please do contact the Pharmig office for payments using AMEX – info@pharmig.org.uk

INDUSTRY 32nd Annual Conference
20th & 21st November, Nottingham

Member Fee £400 (Join Now) / Non-Member Fee £550

Key Topics covered this year include

  • MHRA – A regulatory vision for where Pharma Micro industry is now and where it ‘could’ go. What should companies be thinking about
  • A global review and standardisation of the approach to the use of environmental isolates in AstraZeneca microbiology laboratories.
    Karen Capper, Director – Head of Microbiology, AstraZeneca
  • An updated review of reported recalls involving microbiological control with emphasis on FDA considerations around “Objectionable microorganisms”
    Luis Jimenez – Professor, Bergen Community College (USA) – VIRTUAL
  • Update on the regulatory framework for recombinant technologies for Bacterial Endotoxin Testing (BET) in light of USP developments: A comprehensive overview on the tail of the USP new publication on recombinant reagents
    Veronika Wills – Associate Director, Global Technical Services, Associates of Cape Cod Inc
  • Case study: Identification of contaminants using DNA sequencing
    Elaine Kenny – Managing Director, Elda Biotechnology
  • Establishment of the monocyte activation test as a replacement of the rabbit pyrogen test – a roadmap
    Maria Gajewi – Manager Endotoxin Services, Microcoat
  • Biofilm Remediation
    Dan Klein – Senior Technical Services Manager, Steris
  • Pre-validation considerations for the implementation of an alternative, rapid sterility test method for an Adjuvanted Vaccine portfolio
    Jayendra Shankar – Senior Manager, Global Microbiology QC/AS&T – Seqirus
  • How the EM programme qualification is performed when only part of the facility is operational and what is then to be done to bring the next phases online
    Tracy Moore – Founder & CEO, TM Pharma Group
  • Facts or Fake? Interpretation and significance of microbiological test results
    Frank Mertens – Laboratory Consultant, Saercon
  • Evaluating the impact of Annex 1’s release (steriles & non steriles)
    Andrew Hopkins, Senior Director – Lachman Consultants

Please see attached for more detailed information / fees / booking form

Additional information

Date